14.75
前日終値:
$14.56
開ける:
$14.65
24時間の取引高:
1.47M
Relative Volume:
0.79
時価総額:
$12.31B
収益:
$3.85B
当期純損益:
$667.93M
株価収益率:
22.45
EPS:
0.657
ネットキャッシュフロー:
$142.30M
1週間 パフォーマンス:
+3.29%
1か月 パフォーマンス:
+5.81%
6か月 パフォーマンス:
+4.31%
1年 パフォーマンス:
+4.57%
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
RDY を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
RDY
Dr Reddys Laboratories Ltd Adr
|
14.75 | 11.88B | 3.85B | 667.93M | 142.30M | 0.657 |
![]()
HLN
Haleon Plc Adr
|
11.33 | 49.79B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
ZTS
Zoetis Inc
|
167.14 | 72.11B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
RDHL
Redhill Biopharma Ltd Adr
|
1.76 | 4.24M | 35.75M | 11.57M | -26.25M | -3.8069 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.80 | 45.01B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.53 | 19.43B | 16.54B | -1.64B | 749.00M | -1.45 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-12-19 | ダウングレード | Nomura | Buy → Neutral |
2024-01-11 | ダウングレード | Jefferies | Buy → Underperform |
2023-08-29 | ダウングレード | HSBC Securities | Buy → Hold |
2023-05-18 | ダウングレード | Bernstein | Outperform → Mkt Perform |
2023-03-17 | アップグレード | BofA Securities | Neutral → Buy |
2023-01-30 | 開始されました | JP Morgan | Underweight |
2022-11-14 | ダウングレード | Credit Suisse | Neutral → Underperform |
2022-01-03 | 再開されました | BofA Securities | Neutral |
2021-07-27 | ダウングレード | Credit Suisse | Outperform → Neutral |
2021-02-02 | アップグレード | Barclays | Equal Weight → Overweight |
2020-09-18 | アップグレード | BofA Securities | Neutral → Buy |
2020-09-18 | アップグレード | Investec | Sell → Hold |
2020-01-28 | ダウングレード | CLSA | Buy → Outperform |
2020-01-27 | ダウングレード | CLSA | Buy → Outperform |
2020-01-09 | アップグレード | Citigroup | Sell → Buy |
2019-11-04 | ダウングレード | BofA/Merrill | Buy → Neutral |
2019-09-04 | アップグレード | Credit Suisse | Underperform → Outperform |
2019-07-01 | アップグレード | Macquarie | Neutral → Outperform |
2019-06-20 | 開始されました | Deutsche Bank | Hold |
2019-06-11 | 開始されました | Barclays | Equal Weight |
2019-05-20 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2019-02-19 | アップグレード | CLSA | Outperform → Buy |
2019-01-17 | ダウングレード | Citigroup | Neutral → Sell |
2017-09-21 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2017-08-31 | アップグレード | CLSA | Underperform → Outperform |
2017-07-28 | ダウングレード | CLSA | Underperform → Sell |
2016-07-27 | ダウングレード | HSBC Securities | Hold → Reduce |
2016-07-27 | ダウングレード | Jefferies | Hold → Underperform |
2016-02-10 | アップグレード | Credit Agricole | Underperform → Buy |
2015-11-10 | ダウングレード | Citigroup | Buy → Neutral |
すべてを表示
Dr Reddys Laboratories Ltd Adr (RDY) 最新ニュース
Asian Equities Gain In US Markets' Positive Start - Finimize
Indian ADRs Surge in US Markets as Wall Street soars after US-China trade talks - Moneycontrol
Asian Equities Climb Despite Weekly Losses - Finimize
Dr. Reddy’s Laboratories Grants Stock Options to Employees in May 2025 - TipRanks
Insider’s View: Deciphering Six Flags Entertainment Corp (FUN)’s Financial Health Through Ratios - DWinneX
Balance Sheet Breakdown: Astrazeneca plc ADR (AZN)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Ratio Examination: Dr. Reddy’s Laboratories Ltd. ADR (RDY)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Metric Deep Dive: Understanding Phio Pharmaceuticals Corp (PHIO) Through its Ratios - DWinneX
Financial Analysis: Spotify Technology S.A (SPOT)’s Ratios Unveil Key Insights - DWinneX
5 Indian ADRs crash up to 14% amid rising India-Pakistan military conflict - Trade Brains
Indian Markets Set for Bloody Friday as Gift Nifty Signals Sharp Gap-Down Open Amid Escalating India-Pak Tensions - outlookbusiness.com
Indian ADRs slump as India-Pakistan conflict sees escalation - Moneycontrol
Gift Nifty, India ADRs see sharp sell-off following escalation in India-Pakistan conflict - Moneycontrol
Validea's Top Health Care Stocks Based On Peter Lynch5/5/2025 - Nasdaq
Asian ADRs See Mixed Results Despite Weekly Gains - Finimize
Dr. Reddy’s Laboratories Ltd. ADR (RDY) Performance and Fundamentals Dashboard tells a completely different story - Sete News
Dr. Reddy’s Looks Well Positioned for Long-Term Growth, Aided by Acquisitions and Partnerships - Morningstar
Investing in Dr. Reddy’s Laboratories Ltd. ADR (RDY): What You Must Know - knoxdaily.com
Dr Reddys Share Price Highlights: Dr. Reddys Stock Price History - The Economic Times
LLY Stock Quote Price and Forecast - CNN
NVO Stock Quote Price and Forecast - CNN
Zacks Industry Outlook Dr. Reddy's, Sandoz And Teva Pharmaceuticals - Barchart.com
Asian ADRs Climb, Showcasing North And South Asia Performances - Finimize
PDD Holdings Stock Delivers Phenomenal 5.82% Surge to $95.77 on April 14 – Bullish Momentum Lifts Chinese Tech - Hindustan Herald
3 Generic Drug Stocks To Watch Amid Trade War Jitters & Inflation Woes - Barchart.com
Dr Reddy’s may cut workforce by 25%, including those in Rs 1 crore bracket: Report - financialexpress.com
Asian ADRs Shine As Zai Lab And CNFinance Lead The Gains - Finimize
Dr. Reddy's Laboratories Limited (NYSE:RDY) Shares Acquired by Massachusetts Financial Services Co. MA - MarketBeat
Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading - TradingView
Mixed Performance For Asian Stocks Traded On US Markets - Finimize
Vanguard Group Inc. Purchases 3,911,404 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) - Defense World
Asian Equities Traded in the US as American Depositary Receipts Tumble in Thursday Trading - TradingView
TCS Q4 Results Highlights: Tata Group's IT giant reports slowest revenue growth in 4 years; US tariff hurt client deals - Mint
US Tariffs on Pharma: Dr Reddy's to Sun Pharma—can Indian drugmakers escape Trump's tariff tantrums? - Mint
Dr Reddy's Slapped Rs 2,395 Cr Income Tax Notice, Pharma Giant Denies Allegations - Medical Dialogues
Asian Equities Traded in the US as American Depositary Receipts Sharply Lower in Monday Trading - TradingView
Stocks to watch, April 7: IT, pharma, metals, oil-sensitive stocks, Nykaa, Dr Reddy's, Delhivery, Trent Ltd, and more - Upstox
Dr Reddy's gets over Rs 2,395 crore show cause notice from I-T authority - Moneycontrol
TCS, Dr Reddy's Labs among 6 large and mid-cap stocks that hit 52-week lows on Friday - The Economic Times
Asian Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading - TradingView
Sensex Today | Stock Market Highlights: Sensex falls 322 points, Nifty slips 82 points as IT drags - CNBC TV18
Asian Equities Traded in the US as American Depositary Receipts Trending Lower in Wednesday Trading - TradingView
Generics Industry: India Celebrates Pharmaceutical Tariffs Exemption but Uncertainty Remains High - Morningstar
US Tariffs on Pharma: Zydus, Dr Reddy’s at highest risk, says Jefferies; Check impact on other Indian pharma stocks - Mint
Dr. Reddy's Laboratories Limited (NYSE:RDY) Shares Acquired by GQG Partners LLC - MarketBeat
American Healthcare REIT Inc (AHR) Stock: A Year of Decreases and Increases - The InvestChronicle
Dr Reddys Laboratories Ltd Adr (RDY) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):